Early Research Explores New Two-Fold Strategy for CAR-T Therapy
 

• Dual-target cancer detection: Oren Moscovitz and team have engineered CAR-T cells to combine traditional antigen recognition with a new cysteine-based sensor to detect cancer cells’ altered redox state, overcoming tumor evasion.
• Promising preclinical results: In lab tests and mouse models, these bifunctional CAR-T cells selectively destroyed cancer cells (including lymphoma lines) without harming healthy tissue.
• Broad therapeutic potential: Early data suggest applicability across multiple cancer types, including hard-to-treat forms like certain breast cancers, paving the way for more precise and effective treatments.

 

Researchers are exploring a new, promising strategy to improve conventional CAR-T cell therapies for various cancer types and reduce the likelihood of relapse. The approach is still in its early stages, tested only in the lab and in mice, but scientists led by Oren Moscovitz are determined to push this exciting technology forward towards better treatment for cancer patients.

How Conventional CAR-T Cells Work

CAR-T cells have been used for about a decade to treat certain cancers. Their full name — Chimeric Antigen Receptor T Cells — reveals their mechanism. These are white blood cells (T cells) that scientists modify with synthetic receptors, much like the mythological chimera combined body parts from different animals. In this case, T cells are engineered to carry a receptor that recognizes a specific protein (an antigen) on the surface of cancer cells. Once they latch onto it — like a key fitting into a lock — the T cells destroy the malignant cell.

“But some cancer cells, especially those that survive the initial treatment, manage to hide this marker and slip past CAR-T detection,” explains PhD candidate Jost Lühle.
“We wanted to equip CAR-T cells with an additional method to identify and destroy cancer cells, even when their prime antigen target is missing.”

Equipping CAR-Ts with a Cysteine Sensor

There is, in fact, another characteristic feature of cancer cells — technically known as their altered redox state. It is a complex chemical fingerprint, with fluctuating ratios of certain reactive molecules, making it hard to pinpoint. To complicate matters, even healthy cells can sometimes temporarily show a similar surface chemistry profile.

Moscovitz and his team introduced cysteine, a small amino acid with a reactive chemical group, into the CAR-T cells. Cysteine acts like a chemical glue, giving the CAR-T cell a second way to recognize and bind cancer cells.

“When we tested these cysteine-enhanced CAR-T cells in the lab, we saw that they could detect the altered chemical ‘fingerprint’ of several lymphoma cell lines,” says Moscovitz.

Further tests in mice confirmed that this tweak is not only effective — it is also safe. The modified CAR-T cells selectively targeted only cancer cells, leaving healthy tissue untouched.

A Blueprint for More Effective Cancer Therapies

Initial tests on breast cancer cells show promise for applying the method across multiple forms of cancers, even those that have so far proved more resilient to conventional therapies. Moscovitz and his collaborators continue to work on bifunctional CAR-T cells to combine classic antigen recognition with a second layer of redox-based sensing. Despite being in its earliest days, this approach outlines a new tool that could offer more efficient and precise therapies in the fight against cancer.